Teva Canada Says Aermony RespiClick To Treat Bronchial Asthma Available In Three Dose Options

Teva Canada, a unit of Teva Pharmaceutical Industries Ltd. (TEVA), announced Monday the product availability of Aermony RespiClick, a new device for the treatment of bronchial asthma.

The new device is indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older and offered in a simple-to-use inhaler.

Aermony RespiClick is available in three dose options: 55 mcg, 113 mcg, and 232 mcg per actuation. It is dosed as one inhalation twice daily at the same time every day, approximately 12 hours apart.

Asthma is a chronic inflammatory disease of the airway that causes trouble breathing. Inhalers are the cornerstone of treatment, but, despite the potential benefits of inhaler therapy, evidence suggests that many patients do not use their inhalers correctly.

Anthony D'Urzo, a practising family physician and researcher at the University of Toronto, said, "Devices play a central role in the success of asthma therapy... Aermony RespiClick has desirable 'user-friendly' features that make it a welcome addition for patients who require maintenance therapy with a medication like fluticasone propionate."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately... Drug major Eli Lilly And Co. reported Tuesday weak profit in its second quarter, despite higher revenues driven by strong volume across core business and most major geographies. Further, the company trimmed its forecast for fiscal 2021 earnings on a reported basis and margin, while maintained adjusted earnings view above market estimates. The company also tightened full-year revenue forecast. Shares of BMW Group were losing around 5 percent in German trading after the luxury automaker warned Tuesday that its second half-year is likely to be more volatile, affected by supply bottlenecks, high prices for raw materials and a shortage of semiconductors. This was despite reporting strong second-quarter results driven by solid demand.
Follow RTT